Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

n the gain on sale of Insmed's follow-on biologics (FOB) assets to Merck in March 2009.  The lower interest expense was due to the reduction of the debt discount amortization associated with the Company's 2005 convertible notes which were fully paid off in 2010.

For the year-ended December 31, 2010, revenues totalled $6.9 million, as compared to $10.4 million for the year-ended December 31, 2009.  The reduction was primarily due to a year-over-year decrease of $2.3 million in cost recovery from Insmed's IPLEX EAP in Europe, a $1.0 million reduction in grant revenue related to the 2009 receipt of a $1.0 million grant from the MDA and $0.1 million in reduced royalties.  The causes of the fourth quarter revenue variance were also responsible for the full-year differences in revenue between 2010 and 2009.

Net loss for the 12-months ended December 31, 2010 was $6.4 million, or $0.49 per share, compared to a net income of $118.4 million, or $9.31 per share, for the corresponding 12-months of 2009.  This $124.8 million variance was due to the $127.0 million after tax gain on the sale of the Company's FOB assets to Merck in 2009, combined with a $3.5 million decrease in total revenues. These were partially offset by a $4.0 million reduction in total expenses, a $1.0 million increase in investment returns and a $0.7 million decrease in interest expense.

The $4.0 million decrease in total expenses was due to a $4.4 million reduction in R&D Expenses, which was partially offset by a $0.4 million increase in SG&A Expenses.  The $4.4 million reduction in R&D Expenses was due primarily to a decrease in manufacturing expenses following the sale of Insmed's FOB assets in March 2009, and was partially offset by the ARIKACE-related R&D Expenses incurred in December 2010.  The $0.4 million increase in SG&A Expenses was due largely to the increased finance, legal and consulting fees related to the strategic review an
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Avure Technologies celebrates a year ... newest member of its fleet of high volume High Pressure ... anniversary as we return to PackExpo this year, which is ... Las Vegas,” said Jeff Williams, CEO at Avure. “Sales of ... pleased to be meeting the challenges of market demand for ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 /PRNewswire/ ... GNBT) today announced two presentations demonstrating that the ... novel proprietary cancer immunotherapeutic AE37 vaccine correlated with ... The AE37 cancer vaccine is being developed by ... www.antigenexpress.com ). The presentations are being made at ...
(Date:10/27/2014)... The report “Smart Highway Market by Technology ... and by Display (Variable Message Signs, Digital Signage) ... market into various sub-segments with in-depth analysis and ... and restraints for this market with insights into ... tables and 37 figures spread through 141 pages ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... , , WILMINGTON, Del., ... dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) ... proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly ... formulators have come to expect from a quick-dissolve dosage form. ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of ... issues, finds that the entry and uptake of premium-priced biologics will ... from approximately $420 million in 2008 to nearly $2 billion in ... Systemic Lupus Erythematosus finds that the primary drivers of ...
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences ... a Joint Development Agreement (JDA) to work on the production of ... platform and operational capabilities to advance the development of a step-change ... , Under the terms of the multi-year agreement, Martek ...
Cached Biology Technology:Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
(Date:10/28/2014)... University Singapore (NTU Singapore) will be building a ... energy sources. , The first in the region, ... integration of solar, wind, tidal-current, diesel, storage and ... well together. , To be built under the ... the hybrid micro-grid will be located offshore at ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
Breaking Biology News(10 mins):NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... year in the Horn of Africa affected millions of people ... of several migratory songbird species, a study from University of ... the migration route was revealed by data collected from small ... an extended stay in the Horn of Africa. , The ...
... Entomologist Marshall Johnson , an extension specialist and ... the Distinguished Scientist of the Year Award from the ... (IOBC-NRS). Only one individual is recognized annually for ... career in the nearctic region , which encompasses ...
... DNA self-assembly techniques, researchers have developed a new ... the time required to create and test medications. ... Foundation (NSF) Small Business Innovation Research grant, researchers ... and began evaluating a drug for combating the ...
Cached Biology News:Drought in the Horn of Africa delays migrating birds 2UC Riverside entomologist named Distinguished Scientist of the Year 2Drag-and-drop DNA 2Drag-and-drop DNA 3Drag-and-drop DNA 4
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... extraction of DNA from agarose gels The SpinPrep ... of 150 bp to > 12,000 bp in size ... dissolve the gel slice, followed by adsorption of the ... format. After a wash step, the purified DNA is ...
Biology Products: